Skip to main content
linkedin
CALL:
1-855-344-3298
| AUSTIN | CORPUS CHRISTI | BOSTON
Hit enter to search or ESC to close
Close Search
Menu
HOME
ABOUT
PRACTICE AREAS
ANTITRUST
CIVIL RIGHTS
NEWS
RESOURCES
CONTACT
CALL:
1-855-344-3298
| AUSTIN | CORPUS CHRISTI | BOSTON
HOME
ABOUT
PRACTICE AREAS
ANTITRUST
CIVIL RIGHTS
NEWS
RESOURCES
CONTACT
Category
Antitrust
Antitrust
Pharma Giants’ $454M Glumetza Antitrust Deal Gets Initial OK
Antitrust
Lupin agrees to pay $150 mln to settle Glumetza antitrust claims
Antitrust
Bausch to pay $300 mln in antitrust suit over diabetes drug
Antitrust
Takeda Can’t Duck Generic-Drug Delay Suit at 2nd Circ.
Antitrust
Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza
Antitrust
2nd Circ. Questions Takeda’s ‘Lazarus’ Take On Drug Patents
Antitrust
Glumetza Buyers Get Cert. In Suit Over 800% Price Jump
Antitrust
Gilead Can’t Fend Off Antitrust Suit Over HIV Drug Pricing (3)
Antitrust
HIV Drug Suit Against Gilead, BMS And Janssen Trimmed
Antitrust
IMPAX CAN’T USE ‘UNRELATED BENEFITS,’ AGS TELL 5TH CIRC.
1
2
Next
Search
Recent Posts
Mexico files 2nd lawsuit against arms dealers in US
U.S. States, Cities, and Experts Back Mexico’s Lawsuit Against Gunmakers
Pharma Giants’ $454M Glumetza Antitrust Deal Gets Initial OK
Lupin agrees to pay $150 mln to settle Glumetza antitrust claims
Bausch to pay $300 mln in antitrust suit over diabetes drug
Recent Comments
Recent Comments